The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing (Business Wire)

PARSIPPANY, N.J.----The Medicines Company announced receipt of a not approvable letter from the U.S. Food and Drug Administration on a supplemental New Drug Application for an additional dosing regimen for Angiomax® in the treatment of acute coronary syndromes initiated in the emergency department. [read full story]